Cancer diagnostic companies Exact Sciences and Genomic Health are combining in a $2.8 billion a cash-and-stock deal.
The companies said Monday that they expect to generate revenue of $1.6 billion and gross profit of $1.2 billion in 2020. The deal is expected to close this year.
For each share of Genomic Health they own, shareholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences, subject to a 10% “collar” in case of big stock price fluctuations.
Genomic Health Inc., based in Redwood City, California, specializes in genomic-based diagnostic tests for use in cancer care. Exact Sciences Corp., based in Madison, Wisconsin, focuses on early detection of cancer.
Pfizer to buy Array BioPharma in deal worth $11.4 billion
© 2019 The Associated Press. All rights reserved.
Cancer diagnostic firms to join in $2.8 billion deal (2019, July 29)
retrieved 29 July 2019
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.